Effect of latanoprost acid and pilocarpine on cultured rabbit ciliary muscle cells

Ophthalmic Research

Volumn 39, Issue 4, 2007, Pages 232-240

  Zhong, Yisheng ^a   Gao, Jian ^a   Ye, Wen ^b   Huang, Ping ^a   Cheng, Yu ^a   Jiao, Qin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Calcium ion; Ciliary muscle cells; Latanoprost acid; Matrix metalloproteinase; Pilocarpine; Rabbit; Tissue inhibitors of matrix metalloproteinase

Indexed keywords

INTERSTITIAL COLLAGENASE; LATANOPROST; PILOCARPINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CELL STRUCTURE; CILIARY MUSCLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ANALYSIS; FLUORESCENCE; LASER MICROSCOPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STATISTICAL ANALYSIS;

ANIMALS; CALCIUM; CELLS, CULTURED; CILIARY BODY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; INTRACELLULAR MEMBRANES; MATRIX METALLOPROTEINASE 1; MYOCYTES, SMOOTH MUSCLE; OSMOLAR CONCENTRATION; PILOCARPINE; PROSTAGLANDINS F, SYNTHETIC; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 34547789377     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104832     Document Type: Article

References (45)

1. Alm A, Widengård I, Kjellgren D, et al: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-16.
2. Alm A, Stjernschantz J; the Scandinavian Latanoprost Study Group: Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening and morning. A comparison with timolol. Ophthalmology 1995;102:1743-1752.
3. Camras CB; the United States Latanoprost Study Group: Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-147.
4. Watson P, Stjernschantz J; the Latanoprost Study Group: A six-month randomized double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137.
5. Mishima HK, Masuda K, Kitazawa Y, et al: A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-939.
6. Camras CB, Alm A, Watson P, et al: Latanoprost, a prostaglandin analog, for glaucoma treatment. Efficacy and safety after one year of treatment in 198 patients. Ophthalmology 1996;103:1916-1924.
7. Watson PG; the Latanoprost Study Group: Latanoprost - Two years' experience of its use in the United Kingdom. Ophthalmology 1998;105:82-87.
8. 2α analogue. Adv Prostaglandin Thromboxane Leukot Res 1995;23:513-518.
9. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN: Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci 1997;38:2214-2223.
10. 2α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999;117:794-801.
11. Ocklind A: Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res 1998;67:179-191.
12. Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD: Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-2780.
13. 2α-isopropyl ester treatment. Arch Ophthalmol 2001; 119: 1165-1170.
14. Nagase H, Woessner JFJ: Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
15. Woessner JFJ: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
16. Kaufman PL, Gabelt BT: Direct, indirect, and dual-action parasympathetic drugs; in Zimmerman TJ, Kooner KS, Sharir M, Fechtner RD (eds): Textbook of Ocular Pharmacology. Philadelphia, Lippincott-Raven, 1997, pp 221-238.
17. Bill A: Effects of atropine and pilocarpine on aqueous humour dynamics in cynomolgus (Macaca irus). Exp Eye Res 1967;6:120-125.
18. 2α. Arch Ophthalmol 1987;105:1112-1116.
19. 2αon IOP in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 1990;31:150.
20. 2α analogue PhXA41 in eyes treated with pilocarpine and timolol. Invest Ophthalmol Vis Sci 1992;33:1248.
21. Friström B, Nilsson SEG: Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol 1993;111:662-665.
22. Kent AR, Vroman DT, Thomas TJ, Herbett RL, Crosson CE: Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma 1999;8:257-262.
23. Shin DH, McCracken MS, Bendel RE, et al: The additive effect of latanoprost to maximum tolerated medications with low-dose, high-dose and no pilocarpine therapy. Ophthalmology 1999;106:386-390.
24. Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R: Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997;124:279-286.
25. Lindén C, Alm A: Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol 1997;115:857-861.
26. Teus GMA, Arranz ME, Morales BJ, Marcos DLHA: Ocular hypotensive effect of pilocarpine in latanoprost-treated eyes: a pilot study. Arch Soc Esp Oftalmol 2000;75:735-740.
27. Husain S, Kaddour-Djebbar I, Abdel-Latif AA: Alterations in arachidonic acid release and phospholipase C-beta(1) expression in glaucomatous human ciliary muscle cells. Invest Ophthalmol Vis Sci 2002;43:1127-1134.
28. Tyagi SC, Kumar S, Glover G: Induction of tissue inhibitor and matrix metalloproteinase by serum in human heart-derived fibroblast and endomyocardial endothelial cells. J Cell Biochem 1995;58:360-371.
29. Bernstein P: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. Am J Ophthalmol 2004;137:387-388.
30. Graverand LMP, Eggerer J, Vignon E, Otterness IG, Barclay L, Hart DA: Assessment of specific mRNA levels in cartilage regions in a lapine model of osteoarthritis. J Orthop Res 2002;20:535-544.
31. Ottino P, Taheri F, Bazan HE: Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 and TIMP-1 and -2. Exp Eye Res 2002;74:393-402.
32. 2+ in heart and vascular smooth muscle cells. Can J Physiol Pharmacol 2000;78:162-172.
33. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN: Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol 1997;41:S53-S59.
34. 2α. Exp Eye Res 1988;47:761-769.
35. 2α: an ultrastructural study in rhesus and cynomolgus monkeys. Mech Ageing Dev 1990;51:101-120.
36. Weinreb RN, Lindsey JD: Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 2002;43:716-722. 37 Weinreb RN, Lindsey JD, Luo XX, Wang TH: Extracellular matrix of the human ciliary muscle. J Glaucoma 1994;3:70-78.
37. Rittig M, Lütjen-Drecoll E, Rauterberg J, Jander R, Mollenhauer J: Type VI collagen in the human iris and ciliary body. Cell Tissue Res 1990;259:305-312.
38. Anthony TL, Lindsey JD, Weinreb RN: Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells. Invest Ophthalmol Vis Sci 2002;43:3705-3711.
39. Sanders KM: Invited review: mechanisms of calcium handling in smooth muscles. J Appl Physiol 2001;91:1438-1449.
40. Bolton TB, Prestwich SA, Zholos AV, Gordienko DV: Excitation-contraction coupling in gastrointestinal and other smooth muscles. Annu Rev Physiol 1999;61:85-115.
41. Makhlouf GM, Murthy KS: Signal transduction in gastrointestinal smooth muscle. Cell Signal 1997;9:269-276.
42. 2+ mobilization and heterotrimeric G protein activation in mediating tyrosine phosphorylation signaling patterns in vascular smooth muscle cells. Mol Cell Biochem 2000;212:91-98.
43. 2+ signalling in rat vascular smooth muscle cells: a role for protein kinase C at physiological vasoconstrictor concentrations of vasopressin. J Physiol 2000;524:821-831.
44. White C, McGeown JG: Regulation of basal intracellular calcium concentration by the sarcoplasmic reticulum in myocytes from the rat gastric antrum. J Physiol 2000;529:395-404.
45. Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME: Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001;131:722-728.